CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here.
“Thyroid eye disease is known to cause inflammation, expansion and fibrosis of extraocular muscles and connective tissue of the orbit. The mechanism involves upregulation of TSHR and IGF-1R complex in orbital fibroblasts,” Edith R. Reshef, MD, of Massachusetts Eye and Ear, said at the ASOPRS Fall Scientific Symposium. “Teprotumumab inhibits this pathway, thereby decreasing